|Bid||141.60 x 100|
|Ask||147.17 x 100|
|Day's Range||142.37 - 144.63|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||62.43|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.
The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.
Dr. Reddy's Laboratories (RDY) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes.